Drug-eluting coronary stents: Hypersensitivity reactions to paclitaxel - A case report

Dermatology

Volumn 218, Issue 1, 2008, Pages 52-55

  Pfoch, L ^a   Mahler, V ^a   Sticherling, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Drug eluting stents; Hypersensitivity reactions; Paclitaxel; Taxus

Indexed keywords

CLEMASTINE; IMMUNOGLOBULIN E; LEVOCETIRIZINE; PACLITAXEL; RANITIDINE;

AGED; ARTHRITIS; ARTICLE; ASTHMA; CASE REPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DELAYED HYPERSENSITIVITY; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; HUMAN; MALE; NIGHT SWEAT; PRICK TEST; PRIORITY JOURNAL; PRURITUS; SKIN TEST; SYNOVITIS; TENOSYNOVITIS; TREATMENT DURATION; URTICARIA;

AGED; ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; CARDIOVASCULAR AGENTS; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG HYPERSENSITIVITY; DRUG-ELUTING STENTS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; PACLITAXEL; TREATMENT OUTCOME;

EID: 58149093386     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000171817     Document Type: Article

References (14)

1. Laarmann GJ, Suttorp MJ, Dirksen MT, van Heerebeck L, Kiemeneij F, Slagboom T, et al: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113.
2. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, et al: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-1104.
3. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ: A hierarchical bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-591.
4. Azarbal B, Currier JW: Allergic reactions after the implantation of drug-eluting stents. J Am Coll Cardiol 2006;47:182-183.
5. Turkoglu S, Simsek V, Abaci A: Possible anaphylactic reaction to Taxus stent: a case report. Catheter Cardiovasc Interv 2005;66:554-556.
6. Lehoczky O, Bagaméri A, Udvary J, Pulay T: Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients. J Obstet Gynecol 2002;22:312-313.
7. Boehm DK, Maksymiuk AW: Paclitaxel premedication regimens. J Natl Cancer Inst 1996;88:463-465.
8. Coors E, Seybold H, Merk HF, Mahler V: Polysorbat 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allerg Asthma Immunol 2005;95:593-599.
9. Nebeker J, Virmani R, Bennet CL, Hoffman JM, Samore MH, Alvarez J, et al: Hypersensitivity cases associated with drug-eluting coronary stents. J Am Coll Cardiol 2006;47:175-181.
10. Tsimikas S: Drug-eluting stents and late adverse clinical outcomes. J Am Coll Cardiol 2006;47:2112-2115.
11. McFadden EP, Stabile E, Regar E, Cheneau E, Onq AT, Kinnaird T, et al: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
12. Garber K: Improved paclitaxel formulation hints at new chemotherapy approach. J Natl Cancer Inst 2004;96:90-91.
13. Itoh Y, Sendo T, Hirakawa T, Goromaru T, Takasaki S, Yahata H, et al: Sensory nerve peptides rather than mast cell histamine are involved in paclitaxel hypersensitivity reactions. Am J Respir Crit Care Med 2004;169:113-119.
14. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al: Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-2713.